First Wave Biopharma Stock Beta
FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
First |
First Wave BioPharma Company Beta Analysis
First Wave's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current First Wave Beta | 1.28 |
Most of First Wave's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, First Wave BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, First Wave BioPharma has a Beta of 1.281. This is 48.95% higher than that of the Biotechnology sector and 7.84% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
First Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.First Wave is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, First Wave will likely underperform.
First Fundamentals
Return On Equity | -0.15 | |||
Return On Asset | -0.27 | |||
Current Valuation | 72.56 M | |||
Shares Outstanding | 2.03 M | |||
Shares Owned By Insiders | 5.66 % | |||
Shares Owned By Institutions | 1.46 % | |||
Number Of Shares Shorted | 46.6 K | |||
Price To Book | 1.87 X | |||
EBITDA | (15.74 M) | |||
Net Income | (15.79 M) | |||
Cash And Equivalents | 1.16 M | |||
Cash Per Share | 0.83 X | |||
Total Debt | 826.84 K | |||
Debt To Equity | 0.08 % | |||
Current Ratio | 0.10 X | |||
Book Value Per Share | 7.99 X | |||
Cash Flow From Operations | (12.38 M) | |||
Short Ratio | 1.02 X | |||
Earnings Per Share | (47.88) X | |||
Target Price | 36.0 | |||
Beta | 1.28 | |||
Market Capitalization | 5.99 M | |||
Total Asset | 6.88 M | |||
Retained Earnings | (184.33 M) | |||
Working Capital | 1.82 M | |||
Net Asset | 6.88 M |
About First Wave Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Global Correlations Find global opportunities by holding instruments from different markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |